BIOVECTRA, a subsidiary of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. have announced a strategic collaboration that integrates advanced mRNA sequence design with comprehensive GMP manufacturing capabilities. The partnership grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.
Enhanced mRNA Development Capabilities
The collaboration addresses a critical industry challenge by providing a fully integrated pathway from mRNA sequence design through sterile drug product manufacturing. Through a single agreement, sponsors can access the combined expertise of both organizations, eliminating the need to coordinate across multiple disconnected suppliers.
Revolution Biomanufacturing's proprietary RevSelect™ codon and UTR optimization platform has demonstrated significant improvements in therapeutic performance, achieving up to three- to fivefold increases in protein expression while supporting tissue-specific targeting and extended durability. The technology integrates AI-driven sequence design with advanced process science to accelerate the development of personalized medicines.
Comprehensive Manufacturing Solutions
BIOVECTRA brings extensive GMP manufacturing experience to the partnership, with capabilities spanning clinical-to-commercial scale production for biologics, synthetic small molecules, highly potent APIs, and bioreagents. The company's expertise has expanded into plasmid DNA (pDNA) and mRNA vaccine manufacturing, employing close to 700 people across various scientific and manufacturing roles.
The integrated workflow begins with mRNA sequence design to improve expression and stability, followed by process development, scale-up, technology transfer, and GMP production of plasmid DNA, mRNA, lipid nanoparticles (LNP), and sterile drug product for clinical use.
Industry Impact and Availability
"Too often, therapeutic developers lose time and resources coordinating across disconnected suppliers," said Molly McGlaughlin, Chief Executive Officer of Revolution Biomanufacturing. "By integrating Revolution Biomanufacturing's advanced sequence optimization technologies with BIOVECTRA's end-to-end GMP manufacturing, we're creating a clearer, more reliable path from design to drug product for our customers – one that reduces risks tied to supply disruptions, miscommunication, and failed process transfers."
Normand Blais, AVP, Product Development of BIOVECTRA, emphasized the collaboration's potential: "In pairing Revolution Biomanufacturing's sequence engineering with BIOVECTRA's integrated development and manufacturing solutions, we're helping developers enhance protein expression, determine sequence faster, and move to the clinic with confidence."
Advanced Technology Platform
Revolution Biomanufacturing's vertically integrated platform spans plasmid DNA template production, mRNA synthesis, and lipid nanoparticle formulation, including lyophilized and circular RNA technologies for durable, tissue-targeted delivery. The company is also advancing dual-cargo delivery systems capable of co-encapsulating complementary payloads—such as mRNA and protein, or RNA and small molecules—to enable synergistic therapeutic action.
Service engagements are available immediately for mRNA therapeutics, vaccines, gene-editing therapies, and other nucleic-acid programs, providing the pharmaceutical industry with enhanced capabilities for next-generation therapeutic development.
